Our aim was to evaluate the prognostic and predictive value of two well characterized constitutional MTHFR gene polymorphisms for primarily resected and neoadjuvantly treated esophagogastric adenocarcinomas. This evidence concerns the gene MTHFR and gastroesophageal junction adenocarcinoma.